Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0.

Journal of extracellular vesicles·2026
Same author

Inception and development of a LC-MS/MS assay for the multiplexed quantitation of nine human drug transporter biomarkers.

Bioanalysis·2024
Same author

Proteomic profiling of paired human liver homogenate and tissue derived extracellular vesicles.

Proteomics·2023
Same author

Significance of Organic Anion Transporter 2 and Organic Cation Transporter 2 in Creatinine Clearance: Mechanistic Evaluation Using Freshly Prepared Human Primary Renal Proximal Tubule Cells.

The Journal of pharmacology and experimental therapeutics·2023
Same author

Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.

Pharmaceutical research·2023
Same author

Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides.

Molecular pharmaceutics·2023
Same journal

Targeted Protein Degradation Phenotypic Studies Using HaloTag CRISPR/Cas9 Endogenous Tagging Coupled with HaloPROTAC3.

Current protocols in pharmacology·2020
Same journal

Preclinical Models for Studying the Impact of Macrophages on Cancer Cachexia.

Current protocols in pharmacology·2020
Same journal

In Vitro Permeation Test (IVPT) for Pharmacokinetic Assessment of Topical Dermatological Formulations.

Current protocols in pharmacology·2020
Same journal

A Localized Aldara (5% Imiquimod)-Induced Psoriasiform Dermatitis Model in Mice Using Finn Chambers.

Current protocols in pharmacology·2020
Same journal

Autologously Humanized Mice for Immune-Oncologic Studies.

Current protocols in pharmacology·2020
Same journal

Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.

Current protocols in pharmacology·2020
See all related articles

Related Experiment Video

Updated: May 28, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Cytochrome p450 assays.

Enock Delaporte1, A David Rodrigues

  • 1Merck Research Labs, West Point, Pennsylvania, USA.

Current Protocols in Pharmacology
|October 1, 2011
PubMed
Summary
This summary is machine-generated.

New drug candidates are tested for their ability to inhibit Cytochrome P450s (CYPs), enzymes crucial for drug detoxification. Protocols are described to evaluate potential drug-drug interactions and toxic accumulation of drug levels.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Related Experiment Videos

Last Updated: May 28, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Metabolism

Background:

  • Cytochrome P450s (CYPs) are critical enzymes involved in drug detoxification.
  • Inhibition of CYP-mediated metabolism can result in elevated plasma drug concentrations and potential toxicity.
  • Preventing adverse drug-drug interactions is essential during drug development.

Purpose of the Study:

  • To describe protocols for evaluating new chemical entities as inhibitors of Cytochrome P450 (CYP) activity.
  • To provide methods for assessing the inhibitory potential of drug candidates on CYP enzymes.
  • To facilitate the early identification of compounds that may cause drug-drug interactions.

Main Methods:

  • Utilizing a variety of protocols to assess CYP inhibition.
  • Implementing a high-throughput screening format employing a fluorogenic probe.
  • Describing a method for evaluating time-dependent inhibition of CYP activity by test compounds.

Main Results:

  • Established protocols for evaluating CYP inhibitory activity.
  • Demonstrated a high-throughput screening method for rapid assessment.
  • Provided a method to characterize time-dependent inhibition kinetics.

Conclusions:

  • The described protocols enable comprehensive evaluation of drug candidates' potential to inhibit CYPs.
  • These methods are crucial for predicting and preventing adverse drug-drug interactions.
  • Accurate assessment of CYP inhibition is vital for drug safety and efficacy.